Is GlaxoSmithKline plc still a strong buy after Q3 results?

Bilaal Mohamed shares his views on today’s third-quarter results from GlaxoSmithKline plc (LON:GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has long been a favourite with investors both great and small. Everyone from multi-billion pound fund managers to the granny next door seems to have the global pharmaceuticals giant in their portfolio, and it’s not difficult to see why.

Get-rich-quick schemes

In an age of short-termism and get rich quick schemes, sensible investors know that the first step in generating sustainable long-term wealth lies in capital preservation. It’s for this reason that companies like Glaxo often form part of the core of many well-balanced portfolios, helping to steady the ship in times of political and economic uncertainty.

Along with other defensive sectors such as consumer goods and utilities, multinational pharmaceuticals are less likely to be affected by unforeseen events such as Brexit, or a surprise election win by Donald Trump. Both equity markets and currency markets can collapse and bounce back at a moment’s notice, but these sectors are generally less sensitive to or volatile on the back of such unpredictable political events.

Income investors in particular have had a long-term love affair with Glaxo. Thanks to its capacity to generate enormous profits from worldwide sales each year, the FTSE 100 stalwart can afford to reward its shareholders with generous quarterly payouts that have helped to support the company’s share price through a period when patent expiries have led to increased levels of generic competition for some of its treatments. But what about the future? Is there any hope of growth in such a competitive market?

New York, New York

Commentators like myself had to wait until noon today to get a glimpse of Glaxo’s third-quarter results, rather than the usual 7am regulatory news releases we’re accustomed to here in the UK. The reason? Glaxo is also traded on the New York Stock Exchange (NYSE), and noon equates to 7am Eastern Time. Further proof if it were needed that Glaxo is a true pharmaceutical goliath revered on both sides of the Atlantic.

Today’s results showed continued progress during the third quarter of 2017, with growth in sales and improved operating margins. This was driven by targeted cost savings and restructuring and integration benefits, which in particular helped the Vaccines and Consumer Healthcare businesses, and also supported investment in its new products and Research & Development pipeline. There were also major approvals for its Trelegy Ellipta treatment for Chronic Obstructive Pulmonary Disease (COPD) and shingles vaccine Shingrix.

New product sales up 44%

Pharmaceutical sales were up 3% during the quarter, reflecting continued strong growth of new Respiratory and HIV products, partly offset by a decline in the older products and the impact of recent divestments. Vaccine sales were up 5%, with a strong performance from Meningitis vaccines and continued delivery from influenza products. Consumer Healthcare sales were up 5%, reflecting strong performances from power brands in the Pain and Oral health categories.

But for me, what was most encouraging of all was that sales of new pharmaceutical and vaccine products were up by an impressive 44% to £1.7bn, with total group turnover rising 4% year-on-year to a mammoth £7.8bn.

So is Glaxo still a strong buy after third-quarter results? With its defensive qualities, attractive valuation at less than 14 times forward earnings, and juicy 5.3% yield, the answer has to be a resounding YES.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’d use £3,000 to target a second income that grows each year

Our writer explains the approach he'd take to trying to build a second income that gets bigger over time, by…

Read more »

Elevated view over city of London skyline
Investing Articles

Is it time to buy this incredible FTSE dividend share?

Christopher Ruane examines one FTSE 100 share with a phenomenal dividend history. Does a steep share price fall this year…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

This FTSE 100 share has just crashed another 20%. Its P/E is now just 9.9 so should I buy?

Harvey Jones was tempted to buy this FTSE 100 share after it crashed in October. Now it's crashed again, it…

Read more »

Investing Articles

Could Trump 2.0 be good for FTSE 250 stocks?

Donald Trump’s just been elected President of the United States for a second time. Our writer considers whether this could…

Read more »

Investing Articles

Trading at a 10-year low, this FTSE income stock now yields a chunky 6.99%!

Harvey Jones has been watching from the sidelines as shares in this FTSE 100 income stock just fall and fall.…

Read more »

Dividend Shares

Is a Bank of England rate cut good for the Lloyds share price?

Ken Hall analyses what the latest interest rate cut could mean for the Lloyds share price with the UK bank’s…

Read more »

Investing Articles

2 brilliant bargains I’m considering for my Stocks and Shares ISA!

These FTSE 100 and FTSE 250 shares offer exceptional value on paper. Here's why I'm considering them for my Stocks…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Dividend Shares

How much passive income could I generate with just £10 per day?

Ken Hall wants to create his £10,000 yearly passive income dream by investing just £10 every weekday day in Footsie…

Read more »